DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow DXCM
DexCom, Inc. (DXCM) Free cash flow
DexCom, Inc.'s free cash flow for fiscal 2025 was $1.1B, up 70.8% from $630.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Over the past ten years it has ranged from $500.0K (fiscal 2016) to $2.7B (fiscal 2021); the current reading is higher than 91% of that period. Free cash flow has risen for 3 consecutive fiscal years. DexCom, Inc. ranks 9th of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.1B | 70.79% |
| FY2024 | $630.7M | 23.21% |
| FY2023 | $511.9M | 68.00% |
| FY2022 | $304.7M | (88.80%) |
| FY2021 | $2.7B | 883.22% |
| FY2020 | $276.6M | 105.65% |
| FY2019 | $134.5M | 139.75% |
| FY2018 | $56.1M | 115.77% |
| FY2017 | $26.0M | 5,100.00% |
| FY2016 | $500.0K | (96.82%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $184.5M | (58.91%) |
| Mar 2026 | $449.0M | 133.73% |
| Dec 2025 | $192.1M | (66.85%) |
| Sep 2025 | $579.4M | 177.36% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BSX Boston Scientific Corporation compare | $3.6B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| PHG Koninklijke Philips N.V. compare | $1.8B |
| GEHC GE HealthCare Technologies Inc. compare | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.4B |
| DXCM DexCom, Inc. | $1.4B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $1.0B |
| STE STERIS plc compare | $936.0M |
| PEN Penumbra, Inc. compare | $215.9M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement